Shanghai Allist Pharmaceuticals Co. Ltd. Class ASSE: 688578

Announcement on Voluntary Disclosure of Proposed Inclusion of Furmonertinib Mesylate Tablets for Second-Line Treatment of EGFR Exon 20 Insertion Mutation NSCLC in the Priority Review Process

· Issued by Shanghai Allist Pharmaceuticals Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Proposed Inclusion of Furmonertinib Mesylate Tablets for Second-Line Treatment of EGFR Exon 20 Insertion Mutation NSCLC in the Priority Review Process

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis